Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Alpha Cognition Reports Promising Preclinical Results for ALPHA-1062 in Military-Related Mild TBI Model Alpha Cognition Inc., a biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has announced encouraging preclinical data supporting the continued development of ALPHA-1062 for the…

Read MoreAlpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model
Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment

Vertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment

Vertex Secures EU Approval for ALYFTREK®, a New Once-Daily Treatment for Cystic Fibrosis Vertex Pharmaceuticals announced that the European Commission (EC) has approved ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who…

Read MoreVertex Gains EU Approval for ALYFTREK®, a New Daily Cystic Fibrosis Treatment
OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference

OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference

OS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference OS Therapies a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates (ADCs), has announced encouraging clinical data from its ongoing Phase 2b clinical trial of OST-HER2, a promising…

Read MoreOS Therapies Reports Positive OST-HER2 Survival Data at Osteosarcoma Conference